TSHR; | |
HCAR2; FFAR1; FFAR4; | |
HDAC3; | |
GAA; ACHE; | |
TDP1; RECQL; PKM; GLO1; ALOX12; HSD17B1; HSD17B10; ALOX15; HPGD; AKR1B1; NOX4; USP2; TNKS2; TNKS; PARP1; POLB; CD38; | |
TRPV1; | |
CFTR; | |
IKBKB; GSK3B; SYK; FLT3; EGFR; PIM1; CDK6; CSNK2A1; | |
CA2; CA12; CA7; CA4; | |
AR; | |
PPARA; PPARD; PPARG; | |
ESR2; ESR1; | |
NR1H4; | |
ALOX5; MAOA; PTGS2; PTGS1; MAOB; XDH; | |
KDM4E; | |
MMP9; MMP12; MMP2; | |
TLR2; | |
HIF1A; TP53; NFKB1; | |
SLC22A8; SLC22A6; | |
ABCG2; ABCC1; | |
FABP4; LMNA; NPC1; FABP3; FABP5; FABP2; THPO; TTR; MAPT; APP; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Histone deacetylase | HDAC3 | Histone deacetylase 3 | O15379 | CHEMBL1829 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Oxidoreductase | MAOB | Monoamine oxidase B | P27338 | CHEMBL2039 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Protein Kinase | IKBKB | Inhibitor of nuclear factor kappa B kinase beta subunit | O14920 | CHEMBL1991 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
SLC superfamily of solute carriers | SLC22A8 | Solute carrier family 22 member 8 | Q8TCC7 | CHEMBL1641348 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.308E-10 | 3.956E-08 | CA2, CA7, CD38, CDK6, CFTR, EGFR, HCAR2, HIF1A, NPC1, NR1H4, PARP1, PTGS2, SYK, TNKS, TNKS2, TRPV1 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.979E-10 | 5.671E-08 | CA2, CA7, CFTR, EGFR, HCAR2, HIF1A, NPC1, NR1H4, PTGS2, SYK, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 3.218E-10 | 8.442E-08 | AKR1B1, ALOX12, AR, CD38, CSNK2A1, EGFR, FFAR4, GLO1, GSK3B, HDAC3, HIF1A, IKBKB, LMNA, MMP9, NFKB1, NR1H4, PIM1, PPARD, PTGS2, TP53 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.623E-10 | 1.844E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP3A4, NOX4 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 9.483E-10 | 2.220E-07 | AR, CA12, CA2, CA4, CA7, ESR1, ESR2, GLO1, L3MBTL1, MMP12, MMP2, MMP9, NR1H4, PARP1, PPARA, PPARD, PPARG, TNKS, TP53 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.469E-09 | 3.265E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP3A4, XDH |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 3.287E-09 | 6.752E-07 | ABCC1, ALOX12, ALOX15, ALOX5, SYK, TLR2 |
MF | GO:0005488; binding | GO:0020037; heme binding | 3.615E-09 | 7.289E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP3A4, NOX4, PTGS1, PTGS2 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 5.130E-09 | 9.974E-07 | ALOX12, ALOX15, ALOX5, HPGD, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.861E-08 | 6.137E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 5.560E-08 | 8.466E-06 | AR, ESR1, ESR2, IKBKB, NR1H4, PIM1, PPARA, PPARD, PPARG |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.213E-08 | 9.330E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 7.851E-08 | 1.140E-05 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.941E-07 | 3.577E-05 | CYP1A2, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.973E-07 | 4.677E-05 | CA12, CA2, CA4, CA7 |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 5.801E-07 | 6.579E-05 | CYP19A1, FFAR4, NFKB1, NR1H4, PPARA, PPARD, PPARG |
BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 1.137E-06 | 1.190E-04 | FABP3, FFAR1, NR1H4, PPARG, PTGS2, TLR2 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.162E-06 | 1.211E-04 | CA12, CA2, CA4, CA7, CFTR |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.234E-06 | 1.273E-04 | ABCC1, CA2, CA4, EGFR, HPGD, SLC22A6, SLC22A8, TSHR |
BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.329E-06 | 1.359E-04 | AR, ESR1, ESR2, NR1H4, PPARA, PPARD, PPARG |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.461E-06 | 1.487E-04 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.709E-06 | 1.684E-04 | CYP1A1, POLB, PPARG, TP53 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.709E-06 | 1.684E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 2.889E-06 | 2.700E-04 | APP, CFTR, NOX4, PPARG, PTGS2, TP53, TRPV1 |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 3.244E-06 | 2.955E-04 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 3.565E-06 | 3.208E-04 | FABP2, FABP3, FABP4, FABP5 |
BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 3.748E-06 | 3.345E-04 | APP, EGFR, HDAC3, PARP1, PTGS2, TLR2 |
BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 4.067E-06 | 3.600E-04 | CYP1A1, CYP1A2, MAOB |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 5.297E-06 | 4.436E-04 | AR, ESR1, ESR2, NR1H4, PPARA, PPARD, PPARG |
BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 6.081E-06 | 4.959E-04 | APP, EGFR, MAPT |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 6.589E-06 | 5.309E-04 | AKR1B1, CYP19A1, CYP1A2, MAOB, NOX4, XDH |
BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 8.661E-06 | 6.669E-04 | CA2, CA7, CFTR |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 9.410E-06 | 6.993E-04 | CYP1B1, GSK3B, HCAR2, HPGD, MAPT, MMP9, NOX4, PPARG, PTGS2, TP53, TRPV1, XDH |
BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 9.697E-06 | 7.158E-04 | ALOX12, APP, AR, CA2, CDK6, CYP1B1, EGFR, ESR1, GSK3B, HIF1A, IKBKB, L3MBTL1, MAPT, NR1H4, PIM1, PPARD, PPARG, PTGS2, SYK, THPO, TLR2, XDH |
BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 1.187E-05 | 8.532E-04 | AR, CYP19A1, ESR1 |
BP | GO:0008152; metabolic process | GO:0045944; positive regulation of transcription from RNA polymerase II promoter | 1.305E-05 | 9.223E-04 | APP, AR, EGFR, ESR1, HDAC3, HIF1A, IKBKB, MMP12, NFKB1, NR1H4, PARP1, PPARA, PPARG, TLR2, TNKS, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 1.396E-05 | 9.741E-04 | ALOX12, APP, CD38, CDK6, EGFR, FFAR4, GSK3B, HIF1A, LMNA, NFKB1, NR1H4, PPARD, PPARG, PTGS2, TLR2, XDH |
BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 1.457E-05 | 1.013E-03 | CD38, CYP1A2, EGFR, ESR1, HPGD, PTGS2 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.578E-05 | 1.091E-03 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.578E-05 | 1.091E-03 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.602E-05 | 1.101E-03 | CA12, CA2, CA4, CA7 |
BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 1.645E-05 | 1.126E-03 | ABCG2, APP, CA12, CA2, CA7, CD38, CFTR, EGFR, ESR1, HIF1A, TP53, TRPV1 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.778E-05 | 1.175E-03 | CSNK2A1, EGFR, FLT3, PKM, PPARG |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.780E-05 | 1.175E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 1.780E-05 | 1.175E-03 | PTGS1, PTGS2 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.780E-05 | 1.175E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.780E-05 | 1.175E-03 | ALOX12, ALOX15 |
BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 1.831E-05 | 1.205E-03 | APP, CDK6, EGFR, GSK3B, HDAC3, HIF1A, MAPT, PARP1, PTGS2, SYK, TP53, XDH |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.895E-05 | 1.239E-03 | ALOX15, EGFR, PPARA, PPARD, TP53 |
BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 1.995E-05 | 1.293E-03 | MMP2, MMP9, PPARD, PTGS2 |
BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 2.302E-05 | 1.457E-03 | CYP1A1, CYP1A2, HPGD, MAOB, NFKB1, NR1H4, PPARD, PTGS2 |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 2.425E-05 | 1.513E-03 | AKR1B1, AR, CFTR, EGFR, PPARG |
BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 2.785E-05 | 1.694E-03 | FABP3, PARP1, PKM, PPARA, PPARG, TLR2 |
BP | GO:0032501; multicellular organismal process | GO:0045780; positive regulation of bone resorption | 3.234E-05 | 1.945E-03 | CA2, EGFR, SYK |
BP | GO:0009987; cellular process | GO:0034605; cellular response to heat | 3.937E-05 | 2.311E-03 | MAPT, PTGS2, TP53, TRPV1 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 4.108E-05 | 2.392E-03 | AKR1B1, ALOX5, AR, CDK6, CSNK2A1, ESR1, ESR2, FABP5, GSK3B, HDAC3, HIF1A, HPGD, L3MBTL1, LMNA, NFKB1, NR1H4, PARP1, PIM1, POLB, PPARA, PPARD, PPARG, RECQL, SMN1, SMN2, TNKS, TP53, USP2 |
BP | Unclassified; | GO:0042993; positive regulation of transcription factor import into nucleus | 4.298E-05 | 2.476E-03 | APP, HDAC3, PTGS2, TLR2 |
BP | GO:0002376; immune system process | GO:0001774; microglial cell activation | 4.803E-05 | 2.745E-03 | MAPT, TLR2, TRPV1 |
BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 4.803E-05 | 2.745E-03 | CYP1A1, PPARD, PPARG |
BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 5.326E-05 | 2.962E-03 | APP, TLR2 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 5.326E-05 | 2.962E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 5.326E-05 | 2.962E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 5.326E-05 | 2.962E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 5.326E-05 | 2.962E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 5.326E-05 | 2.962E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 6.563E-05 | 3.555E-03 | AKR1B1, CYP19A1, CYP1A2, MAOB, NOX4, XDH |
MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 6.644E-05 | 3.590E-03 | ACHE, CSNK2A1, EGFR, FLT3, L3MBTL1, MAPT, MMP12, MMP9, PIM1, PKM, PPARA, SYK, TLR2, TSHR |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 8.066E-05 | 4.252E-03 | HIF1A, LMNA, PPARD, PTGS2, TP53 |
BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 8.117E-05 | 4.259E-03 | NOX4, PARP1, POLB, TP53 |
MF | GO:0005488; binding | GO:0043621; protein self-association | 8.117E-05 | 4.259E-03 | ACHE, FLT3, PPARG, TP53 |
BP | GO:0002376; immune system process | GO:0002684; positive regulation of immune system process | 8.317E-05 | 4.353E-03 | APP, CA2, CD38, HCAR2, HIF1A, IKBKB, MMP12, MMP2, NFKB1, NR1H4, SYK, THPO, TLR2, TP53 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 8.829E-05 | 4.556E-03 | HIF1A, MMP12, MMP2, MMP9, TRPV1 |
BP | GO:0051179; localization | GO:0032368; regulation of lipid transport | 9.232E-05 | 4.678E-03 | CYP19A1, NFKB1, PPARA, PPARG, SYK |
BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 9.280E-05 | 4.678E-03 | CA2, HDAC3, PTGS2 |
CC | GO:0044464; cell part | GO:0005829; cytosol | 9.257E-05 | 4.678E-03 | AKR1B1, ALOX12, ALOX15, ALOX5, APP, AR, CA2, CA7, CDK6, CFTR, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GLO1, GSK3B, HDAC3, HIF1A, HPGD, HSD17B1, IKBKB, LMNA, MAPT, NFKB1, PIM1, PKM, PPARG, SMN1, SMN2, SYK, TNKS, TNKS2, TP53, TRPV1, XDH |
BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 9.648E-05 | 4.829E-03 | AKR1B1, CYP1B1, EGFR, MMP9, TP53 |
BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 9.881E-05 | 4.923E-03 | APP, AR, CA2, HIF1A, MAPT, NFKB1, PARP1, PPARD, PPARG, PTGS2, SYK, THPO, TLR2 |
BP | GO:0065007; biological regulation | GO:0055088; lipid homeostasis | 1.052E-04 | 5.163E-03 | FABP3, FABP4, NPC1, NR1H4, PPARG |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.062E-04 | 5.163E-03 | TNKS, TNKS2 |
BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 1.062E-04 | 5.163E-03 | APP, TLR2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.062E-04 | 5.163E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.062E-04 | 5.163E-03 | ESR1, ESR2 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.071E-04 | 5.195E-03 | HPGD, MMP2, MMP9 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.228E-04 | 5.852E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 1.352E-04 | 6.386E-03 | AR, ESR1, GSK3B, PPARA, TP53 |
BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 1.399E-04 | 6.581E-03 | CYP1A1, CYP1A2, PPARG |
BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 1.585E-04 | 7.376E-03 | HIF1A, PPARD, TP53 |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.766E-04 | 8.009E-03 | ALOX12, ALOX15 |
BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 1.766E-04 | 8.009E-03 | PPARA, PPARG |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.766E-04 | 8.009E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.787E-04 | 8.038E-03 | CYP19A1, CYP1A2, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0003950; NAD+ ADP-ribosyltransferase activity | 1.787E-04 | 8.038E-03 | PARP1, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 1.866E-04 | 8.362E-03 | CSNK2A1, EGFR, FLT3, GSK3B, PIM1, SYK |
BP | GO:0051179; localization | GO:0015908; fatty acid transport | 1.887E-04 | 8.436E-03 | FABP3, PPARA, PPARD, PPARG |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.919E-04 | 8.543E-03 | ALOX15, APP, EGFR, FFAR4, NOX4, THPO |
BP | Unclassified; | GO:0042346; positive regulation of NF-kappaB import into nucleus | 2.004E-04 | 8.797E-03 | APP, PTGS2, TLR2 |
BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 2.004E-04 | 8.797E-03 | CYP1B1, HIF1A, PTGS2 |
BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 2.004E-04 | 8.797E-03 | PARP1, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 2.004E-04 | 8.797E-03 | APP, GSK3B, PARP1 |
MF | GO:0005488; binding | GO:0000166; nucleotide binding | 2.151E-04 | 9.347E-03 | ABCC1, ABCG2, CDK6, CFTR, CSNK2A1, EGFR, FLT3, GSK3B, HPGD, HSD17B1, IKBKB, MAOB, NOX4, PARP1, PIM1, PKM, RECQL, SYK, TP53, TRPV1, XDH |
BP | GO:0051179; localization | GO:0015850; organic hydroxy compound transport | 2.222E-04 | 9.534E-03 | ABCG2, CFTR, NPC1, NR1H4, SYK |
BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 2.237E-04 | 9.534E-03 | CYP19A1, CYP3A4, ESR1 |
MF | GO:0005488; binding | GO:0051059; NF-kappaB binding | 2.237E-04 | 9.534E-03 | GSK3B, HDAC3, PPARD |
BP | GO:0050896; response to stimulus | GO:0046683; response to organophosphorus | 2.304E-04 | 9.778E-03 | APP, CFTR, NOX4, PTGS2, TRPV1 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 7.582E-10 | 7.003E-08 | GSK3B; FLT3; MMP2; PTGS2; HIF1A; MMP9; EGFR; NFKB1; IKBKB; AR; CDK6; PPARG; TP53; PPARD |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 8.144E-10 | 7.003E-08 | CYP2C9; APP; MAOB; MAOA; ALOX5; ALOX15; ALOX12; PTGS2; PTGS1 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 5.427E-08 | 2.334E-06 | HSD17B1; ALOX5; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.319E-08 | 7.560E-07 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.019E-07 | 5.788E-06 | CYP2C9; ALOX5; ALOX15; ALOX12; PTGS2; PTGS1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.556E-07 | 8.729E-06 | MAOB; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PTGS2; CYP3A4; CYP19A1; HSD17B10; PTGS1; CYP2C9; PKM; HSD17B1; ALOX5; CYP1A2; CYP1A1; CD38; XDH |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.734E-07 | 8.729E-06 | IKBKB; ABCC1; CDK6; PIM1; CYP1B1; PTGS2; TP53; MMP9; EGFR; NFKB1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.347E-07 | 4.633E-06 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.568E-07 | 8.729E-06 | CA2; NR1H4; SLC22A8; CYP3A4; CFTR; ABCG2 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.748E-06 | 2.312E-05 | IKBKB; GSK3B; AR; TP53; EGFR; NFKB1 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 6.020E-07 | 9.413E-06 | MAOB; MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.077E-06 | 1.544E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; PTGS2 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.627E-06 | 4.159E-05 | IKBKB; FLT3; PIM1; NFKB1; PPARD |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.263E-06 | 2.780E-05 | IKBKB; SYK; CSNK2A1; PARP1; PTGS2; NFKB1 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 7.522E-06 | 7.611E-05 | IKBKB; CDK6; TP53; EGFR; NFKB1 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.999E-05 | 1.454E-04 | MMP2; TP53; HIF1A; ESR1; MMP9; EGFR; TLR2 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.936E-05 | 1.454E-04 | IKBKB; GSK3B; SYK; CSNK2A1; CD38; TP53; NFKB1 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 8.103E-06 | 7.743E-05 | PKM; FLT3; TP53; HIF1A; EGFR |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.129E-05 | 1.465E-04 | POLB; CDK6; PKM; HDAC3; SYK; TP53; NFKB1 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.787E-05 | 1.454E-04 | IKBKB; GSK3B; PPARA; TP53; EGFR; NFKB1 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 9.369E-06 | 8.481E-05 | CYP2C9; MAOB; MAOA; CYP1A2; CYP3A4 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 2.028E-05 | 1.454E-04 | GSK3B; CDK6; CSNK2A1; TP53; NFKB1; TLR2 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.236E-05 | 1.063E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.029E-05 | 1.861E-04 | IKBKB; CDK6; TP53; MMP9; NFKB1; TLR2 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 7.830E-05 | 4.489E-04 | IKBKB; GSK3B; CDK6; SYK; TP53; EGFR; NFKB1; TLR2 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.749E-05 | 1.751E-04 | IKBKB; CDK6; PTGS2; TP53; NFKB1 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 5.417E-05 | 3.213E-04 | MMP2; ESR1; MMP9; EGFR; ESR2 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 9.715E-05 | 5.222E-04 | HPGD; FLT3; PPARG; TP53; MMP9; NFKB1 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.765E-06 | 6.198E-05 | CYP2C9; CYP1A2; ALOX15; CYP3A4 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.247E-04 | 6.499E-04 | GSK3B; HDAC3; TP53; ESR1; HIF1A |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.770E-04 | 1.222E-03 | IKBKB; PARP1; LMNA; TP53; NFKB1 |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.997E-07 | 9.413E-06 | CA12; CA2; CA4; CA7 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 8.196E-05 | 4.548E-04 | FABP4; PTGS2; TSHR; PTGS1 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.368E-05 | 1.566E-04 | MMP2; MMP9; TP53; EGFR |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.184E-04 | 1.043E-03 | GSK3B; ESR1; NFKB1; ESR2 |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.304E-04 | 1.043E-03 | IKBKB; GSK3B; SYK; NFKB1 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.304E-04 | 1.043E-03 | IKBKB; CDK6; TP53; NFKB1 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 9.843E-04 | 4.129E-03 | IKBKB; CSNK2A1; TP53; NFKB1; TLR2 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.469E-04 | 7.432E-04 | CYP2C9; CYP1A2; CYP1A1; CYP3A4 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.053E-03 | 4.259E-03 | IKBKB; GSK3B; PPARA; NFKB1 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.090E-03 | 4.259E-03 | IKBKB; PTGS2; MMP9; NFKB1 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.361E-03 | 5.089E-03 | HCAR2; PPARA; CFTR; NFKB1; TSHR |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.413E-03 | 5.171E-03 | IKBKB; ALOX5; NFKB1; TLR2 |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.503E-03 | 5.386E-03 | IKBKB; GSK3B; TP53; NFKB1 |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.131E-03 | 7.318E-03 | IKBKB; SYK; PPARG; NFKB1 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 2.776E-03 | 8.841E-03 | GSK3B; CSNK2A1; TP53; PPARD |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 3.461E-03 | 1.026E-02 | IKBKB; GSK3B; PPARA; NFKB1 |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 3.981E-03 | 1.141E-02 | IKBKB; MAPT; TP53; EGFR; NFKB1 |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 4.183E-03 | 1.179E-02 | IKBKB; POLB; GSK3B; TP53; NFKB1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 5.053E-03 | 1.380E-02 | APP; GSK3B; MAPT; HSD17B10 |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.416E-03 | 7.992E-03 | CDK6; TP53; EGFR |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.270E-03 | 4.855E-03 | GSK3B; TP53; EGFR |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 3.106E-03 | 9.541E-03 | CDK6; TP53; EGFR |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 8.296E-03 | 2.038E-02 | MMP2; PIM1; NFKB1 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.574E-03 | 5.527E-03 | CDK6; TP53; EGFR |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 2.748E-03 | 8.841E-03 | IKBKB; EGFR; NFKB1 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 3.361E-03 | 1.014E-02 | PTGS2; NFKB1; TLR2 |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 2.984E-03 | 9.332E-03 | IKBKB; PPARA; NFKB1 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 6.811E-03 | 1.748E-02 | PPARG; TP53; NFKB1 |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 8.753E-03 | 2.104E-02 | HIF1A; EGFR; NFKB1 |
hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 5.674E-03 | 1.525E-02 | THPO; FLT3; CD38 |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.068E-03 | 4.259E-03 | MAOB; MAOA; NFKB1 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 8.987E-03 | 2.104E-02 | IKBKB; GSK3B; NFKB1 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 9.465E-03 | 2.171E-02 | IKBKB; NFKB1; TLR2 |
hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 7.218E-03 | 1.826E-02 | CA2; CD38; CFTR |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 8.987E-03 | 2.104E-02 | IKBKB; NFKB1; TLR2 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.323E-02 | 2.917E-02 | ABCC1; TP53; NFKB1 |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.604E-02 | 3.405E-02 | GSK3B; MAOB; MAOA |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.444E-02 | 3.143E-02 | GSK3B; CDK6; TP53 |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 7.793E-04 | 3.351E-03 | ABCC1; CFTR; ABCG2 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.521E-02 | 4.984E-02 | IKBKB; HIF1A |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.291E-02 | 4.582E-02 | IKBKB; NFKB1 |
hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 2.143E-02 | 4.336E-02 | NFKB1; TLR2 |
hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 2.143E-02 | 4.336E-02 | GSK3B; TP53 |
hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 1.791E-02 | 3.712E-02 | MAOB; MAOA |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.658E-02 | 3.478E-02 | IKBKB; PKM |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.529E-02 | 3.288E-02 | CYP3A4; XDH |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 6.275E-03 | 1.660E-02 | PPARG; TP53 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 6.705E-03 | 1.747E-02 | GAA; AKR1B1 |
hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 1.171E-02 | 2.616E-02 | PKM; GLO1 |
hsa00260 | Glycine, serine and threonine metabolism_Homo sapiens_hsa00260 | 1.171E-02 | 2.616E-02 | MAOB; MAOA |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 8.074E-03 | 2.013E-02 | POLB; PARP1 |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 9.051E-03 | 2.104E-02 | MAOB; MAOA |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.973E-03 | 1.141E-02 | CA2; CA4 |
hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 4.322E-03 | 1.199E-02 | MAOB; MAOA |
hsa00360 | Phenylalanine metabolism_Homo sapiens_hsa00360 | 2.170E-03 | 7.318E-03 | MAOB; MAOA |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.647E-04 | 8.095E-04 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1 |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
NA: NA | Upper abdominal bloating | NA | ACHE |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR; PARP1; MMP2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; NFKB1; PPARD; PPARG; PPARG; HCAR2; PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; EGFR; PTGS2 |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1; EGFR; TLR2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR |
C00-D49: Neoplasms | Solid tumours | C00-D48 | SYK; TP53; FLT3; MMP9; EGFR; TLR2; MMP2; PKM; HIF1A |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; ESR1; HCAR2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
C00-D49: Neoplasms | Lymphoma | C81-C86 | EGFR; HIF1A |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; MMP2 |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOA; MAOB; MAOB |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SYK; MMP12; PTGS1; PTGS2 |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG; PTGS1; PTGS2 |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG; MAOB |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4; MAOA; MAOB |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; TRPV1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAOB; MAPT |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP; ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53; CD38 |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
NA: NA | Joint and muscular pain | NA | PTGS2 |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12 |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2 |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
NA: NA | Dyslipidemia | NA | PPARD |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1 |
I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; TRPV1; PTGS1 |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP; ACHE |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG; PTGS2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
NA: NA | Edema | NA | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; TRPV1; PTGS1; PTGS2; PTGS2 |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; HCAR2; MAOB |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
NA: NA | Male hypogonadism | NA | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive episode without melancholia | F30-F39 | MAOB |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
NA: NA | Esophagus sensitivity | NA | TRPV1 |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG; AKR1B1; PTGS2; ABCC1; ABCC1; XDH |
NA: NA | GIST | NA | FLT3 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1 |
NA: NA | Geographic retinal atrophy | NA | APP |
C00-D49: Neoplasms | Glioma | C71 | APP; EGFR; EGFR |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | IKBKB; ALOX5; MMP2; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
C00-D49: Neoplasms | Melanoma | C43 | EGFR; TLR2; PARP1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1 |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Idiopathic parkinson's disease | F02.3, G20 | MAOB |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; EGFR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | IKBKB; AR; AR; ESR1; MMP2; PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1 |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1 |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B; FFAR1; PPARG; AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; MAOB |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | MAOB |
C00-D49: Neoplasms | Multiple myeloma | C90 | CD38 |
C00-D49: Neoplasms | AML | NA | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | IKBKB; GSK3B; APP; ACHE; ACHE; ACHE; MAOA; PPARG; PPARG; MAOB; PTGS2; MAPT |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; SYK |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
I00-I99: Diseases of the circulatory system | Moderate to severe hypertension | I10-I16 | MAOB |
NA: NA | Miosis during ocular surgery | NA | PTGS1 |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; HCAR2 |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; PTGS1 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | IKBKB; ALOX5; PTGS2; PTGS2; ABCC1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1 |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
NA: NA | Motor symptoms | NA | MAOB |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; GSK3B; SYK; APP; TP53; FLT3; FLT3; MMP9; NFKB1; ACHE; ESR1; ESR1; EGFR; TLR2; PIM1; PARP1; MMP2; PTGS2; HIF1A; CD38; CSNK2A1 |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12; PPARD; HCAR2 |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; SYK; SYK; MMP12; TRPV1; PTGS2 |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; TRPV1 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; MAOB |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; SYK; AKR1B1; PTGS2; PTGS2; PTGS2; PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR; AKR1B1 |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; PARP1 |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAOB; MAPT |
NA: NA | Menopausal disorder | NA | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1; TLR2 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAOB; MAPT |
C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; ESR1; ESR1; EGFR; EGFR; EGFR |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
NA: NA | Postmenopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; EGFR |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ACHE; ESR1; TRPV1; TRPV1; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PKM |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; EGFR |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9; EGFR; EGFR; PTGS1 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; EGFR; TLR2; MMP2; PTGS2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |